Contrasting Climb Bio (CLYM) and Its Competitors

Climb Bio (NASDAQ:CLYM) is one of 1,061 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Climb Bio to related businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Climb Bio and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7855	21316	48949	1245	2.55

Climb Bio presently has a consensus target price of $10.00, indicating a potential upside of 344.44%. As a group, “Pharmaceutical preparations” companies have a potential upside of 186.03%. Given Climb Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Climb Bio is more favorable than its peers.

Risk & Volatility

Climb Bio has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Climb Bio’s peers have a beta of 3.66, meaning that their average stock price is 266% more volatile than the S&P 500.

Profitability

This table compares Climb Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Valuation & Earnings

This table compares Climb Bio and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-1.06
Climb Bio Competitors	$9.57 billion	$147.90 million	-5.52

Climb Bio’s peers have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.2% of Climb Bio shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Climb Bio beats its peers on 7 of the 13 factors compared.

Climb Bio Company Profile

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.